137 related articles for article (PubMed ID: 37493453)
21. Velaglucerase alfa: a new option for Gaucher disease treatment.
Zimran A
Drugs Today (Barc); 2011 Jul; 47(7):515-29. PubMed ID: 22013559
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry.
Deegan P; Lau H; Elstein D; Fernandez-Sasso D; Giraldo P; Hughes D; Zimran A; Istaiti M; Gadir N; Botha J; Revel-Vilk S;
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792324
[No Abstract] [Full Text] [Related]
24. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Hughes DA; Gonzalez DE; Lukina EA; Mehta A; Kabra M; Elstein D; Kisinovsky I; Giraldo P; Bavdekar A; Hangartner TN; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):584-91. PubMed ID: 25801797
[TBL] [Abstract][Full Text] [Related]
25. The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States.
Farahbakhshian S; Inocencio TJ; Poorman G; Wright E; Pathak RR; Bullano M
J Med Econ; 2022; 25(1):755-761. PubMed ID: 35611840
[TBL] [Abstract][Full Text] [Related]
26. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.
van Dussen L; Cox TM; Hendriks EJ; Morris E; Akkerman EM; Maas M; Groener JE; Aerts JM; Deegan PB; Hollak CE
Haematologica; 2012 Dec; 97(12):1850-4. PubMed ID: 22773601
[TBL] [Abstract][Full Text] [Related]
27. Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
Kuter DJ; Wajnrajch M; Hernandez B; Wang R; Chertkoff R; Zimran A
Blood Cells Mol Dis; 2020 May; 82():102418. PubMed ID: 32146279
[TBL] [Abstract][Full Text] [Related]
28. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
Zimran A; Wajnrajch M; Hernandez B; Pastores GM
Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
[TBL] [Abstract][Full Text] [Related]
29. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
30. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease.
Elstein D; Hughes D; Goker-Alpan O; Stivel M; Baris HN; Cohen IJ; Granovsky-Grisaru S; Samueloff A; Mehta A; Zimran A
J Obstet Gynaecol Res; 2014 Apr; 40(4):968-75. PubMed ID: 24612151
[TBL] [Abstract][Full Text] [Related]
31. Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations.
Dinur T; Grittner U; Revel-Vilk S; Becker-Cohen M; Istaiti M; Cozma C; Rolfs A; Zimran A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299318
[TBL] [Abstract][Full Text] [Related]
32. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
Zimran A; Elstein D; Gonzalez DE; Lukina EA; Qin Y; Dinh Q; Turkia HB
Blood Cells Mol Dis; 2018 Feb; 68():153-159. PubMed ID: 27839979
[TBL] [Abstract][Full Text] [Related]
33. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.
Deegan P; Fernandez-Sasso D; Giraldo P; Lau H; Panahloo Z; Zimran A
Blood Cells Mol Dis; 2018 Feb; 68():218-225. PubMed ID: 27829541
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease.
Elstein D; Zimran A
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):333-339. PubMed ID: 30736148
[TBL] [Abstract][Full Text] [Related]
35. Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS).
Titievsky L; Schuster T; Wang R; Younus M; Palladino A; Quazi K; Wajnrajch MP; Hernandez B; Becker PS; Weinreb NJ; Chambers C; Mansfield R; Taylor L; Tseng LJ; Kaplan P
Orphanet J Rare Dis; 2022 Apr; 17(1):145. PubMed ID: 35365177
[TBL] [Abstract][Full Text] [Related]
36. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Elstein D; Paz A; Brill-Almon E; Chertkoff R
Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
[TBL] [Abstract][Full Text] [Related]
38. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
[TBL] [Abstract][Full Text] [Related]
40. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
